Kymera Therapeutics (NASDAQ: KYMR) has appointed Elizabeth Laws, Ph.D., as Senior Vice President and KT-621 Development Program Leader, according to a company statement issued July 7, 2026.

Dr. Laws previously served as Senior Vice President, Head of Sanofi Integrated Launch & Commercialization Excellence. She also held roles at Sanofi as Vice President, Head of the Immunology & Inflammation Therapeutic Area, and Vice President, Head of the Dupilumab/Dupixent Development Program. Earlier in her career, she held positions at MDS Pharma and McKinsey & Company.

In her new role, Dr. Laws will oversee global development strategy for KT-621, an oral STAT6 degrader that Kymera describes as first-in-class. The company is running parallel Phase 2b trials for KT-621 in atopic dermatitis and asthma. Enrollment in the atopic dermatitis study is complete, with data expected by year-end 2026. Asthma trial data is expected in late 2027. Phase 3 trials in atopic dermatitis are planned to begin by mid-2027.

"We are thrilled to welcome Liz to Kymera at a pivotal time for our company and the KT-621 program," said Nello Mainolfi, Ph.D., Founder, President and CEO of Kymera Therapeutics. "She brings exceptional experience across immunology clinical development, global franchise strategy and commercialization."

Dr. Laws holds a Ph.D. in Chemistry from the University of California, Berkeley, and bachelor's degrees in Chemistry and Mathematics from Williams College.